Inventor · disambiguated record
Paul P. Tamburini
Also filed as: TAMBURINI PAUL · TAMBURINI PAUL P · TAMBURINI PAUL PERRY
29 granted patents·14 pending applications·645 citations·filing 1992–2025
97Inventor score
Top patents by PatentIndex Score
43 records- 0199US9206251B2Nucleic acids encoding anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Dec 8, 2015·36 cites·36 claims
- 0299US9107861B1Methods of treating C5 mediated complement-associated conditions with anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Aug 18, 2015·58 cites·18 claims
- 0399US9079949B1Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Jul 14, 2015·182 cites·20 claims
- 0498US11434280B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2020·Granted Sep 6, 2022·10 cites·18 claims
- 0598US9663574B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2016·Granted May 30, 2017·24 cites·10 claims
- 0697US10584164B2Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodiesALEXION PHARMA INC·Filed 2019·Granted Mar 10, 2020·11 cites·10 claims
- 0797US10227400B2Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodiesALEXION PHARMA INC·Filed 2017·Granted Mar 12, 2019·14 cites·7 claims
- 0897US9803007B1Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2017·Granted Oct 31, 2017·14 cites·7 claims
- 0997US9371377B2Anti-C5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2015·Granted Jun 21, 2016·22 cites·17 claims
- 1095US9011852B2Anti-C5a antibodiesROTHER RUSSELL P·Filed 2011·Granted Apr 21, 2015·25 cites·18 claims
- 1194US9221901B2Methods of treating complement-associated disorders with anti-C5a antibodiesALEXION PHARMA INC·Filed 2015·Granted Dec 29, 2015·11 cites·16 claims
- 1293US9371378B1Anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted Jun 21, 2016·7 cites·10 claims
- 1391US9309310B2Nucleic acids encoding anti-C5a antibodiesALEXION PHARMA INC·Filed 2015·Granted Apr 12, 2016·7 cites·20 claims
- 1490US12221473B2Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereofALEXION PHARMA INC·Filed 2022·Granted Feb 11, 2025·1 cites·13 claims
- 1589US9469690B2Methods of treating complement-associated disorders with anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted Oct 18, 2016·4 cites·14 claims
- 1689US9434784B1Nucleic acids encodng anti-C5A antibodiesALEXION PHARMA INC·Filed 2016·Granted Sep 6, 2016·4 cites·27 claims
- 1789US2024141024A1Anti-c5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2023·Application pending·0 cites
- 1888US7019123B2Human bikuninBAYER AG·Filed 2001·Granted Mar 28, 2006·35 cites·6 claims
- 1986US6583108B1Human bikuninBAYER AG·Filed 1998·Granted Jun 24, 2003·69 cites·9 claims
- 2085US10450370B2Anti-C5a antibodiesALEXION PHARMA INC·Filed 2018·Granted Oct 22, 2019·2 cites·20 claims
- 2184US11498960B2Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereofALEXION PHARMA INC·Filed 2018·Granted Nov 15, 2022·2 cites·14 claims
- 2284US9963503B2Methods of producing anti-C5a antibodiesALEXION PHARMA INC·Filed 2016·Granted May 8, 2018·2 cites·2 claims
- 2384US2023159627A1Anti-c5a antibodiesALEXION PHARMA INC·Filed 2022·Application pending·0 cites
- 2482US5296604AProline derivatives and compositions for their use as inhibitors of HIV proteaseMILES INC·Filed 1992·Granted Mar 22, 1994·73 cites·12 claims
- 2581US11407821B2Anti-C5A antibodiesALEXION PHARMA INC·Filed 2019·Granted Aug 9, 2022·0 cites·24 claims
- 2678US2025145698A1Anti-c5 antibodies having improved pharmacokineticsALEXION PHARMA INC·Filed 2025·Application pending·0 cites
- 2776US2024293540A1Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5ALEXION PHARMA INC·Filed 2023·Application pending·0 cites
- 2873US12497445B2Monovalent anti-properdin antibodies and antibody fragmentsALEXION PHARMA INC·Filed 2021·Granted Dec 16, 2025·0 cites·8 claims
- 2973US8168758B2Anti-MN antibodies and methods of using sameTAMBURINI PAUL·Filed 2006·Granted May 1, 2012·4 cites·29 claims
- 3072US7452859B2Human bikuninAEROVANCE INC·Filed 2006·Granted Nov 18, 2008·1 cites·7 claims
- 3164US2025163138A1Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereofALEXION PHARMA INC·Filed 2025·Application pending·0 cites
- 3261US11198725B2Monovalent anti-properdin antibodies and antibody fragmentsALEXION PHARMA INC·Filed 2018·Granted Dec 14, 2021·0 cites·7 claims
- 3359US2023357442A1Methods of treating dermatomyositisALEXION PHARMA INC·Filed 2021·Application pending·0 cites
- 3459US2024018220A1Methods of treating patients having complement disorders using anti-c5 antibodiesALEXION PHARMA INC·Filed 2021·Application pending·0 cites
- 3554US5981208ADiagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor proteinBAYER AG·Filed 1994·Granted Nov 9, 1999·24 cites·5 claims
- 3653US2020023060A1Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5ALEXION PHARMA INC·Filed 2019·Application pending·0 cites
- 3751US2016051673A1Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5ALEXION PHARMA INC·Filed 2014·Application pending·0 cites
- 3848US2015247849A1Screening assays for complement component c5 antagonistsTAMBURINI PAUL P·Filed 2013·Application pending·0 cites
- 3939US2014206849A1Antibodies having reduced immunogenicity in a humanTAMBURINI PAUL P·Filed 2011·Application pending·0 cites
- 4039US2012301468A1Anti-mn antibodies and methods of using sameTAMBURINI PAUL·Filed 2012·Application pending·0 cites
- 4137US2011002931A1Bispecific antibodies that bind to complement proteinsALEXION PHARMA INC·Filed 2010·Application pending·0 cites
- 4236US2016168237A1Method for treating a complement mediated disorder caused by an infectious agent in a patientALEXION PHARMA INC·Filed 2015·Application pending·0 cites
- 4329US5833946ADissemination of fungal infections: animal model and method of prophylaxisBAYER AG·Filed 1995·Granted Nov 10, 1998·3 cites·5 claims
Join the waitlist — get patent alerts
Get an alert when Paul P. Tamburini files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →